Literature DB >> 21339361

Protection of nonself surfaces from complement attack by factor H-binding peptides: implications for therapeutic medicine.

You-Qiang Wu1, Hongchang Qu, Georgia Sfyroera, Apostolia Tzekou, Brian K Kay, Bo Nilsson, Kristina Nilsson Ekdahl, Daniel Ricklin, John D Lambris.   

Abstract

Exposure of nonself surfaces such as those of biomaterials or transplanted cells and organs to host blood frequently triggers innate immune responses, thereby affecting both their functionality and tolerability. Activation of the alternative pathway of complement plays a decisive role in this unfavorable reaction. Whereas previous studies demonstrated that immobilization of physiological regulators of complement activation (RCA) can attenuate this foreign body-induced activation, simple and efficient approaches for coating artificial surfaces with intact RCA are still missing. The conjugation of small molecular entities that capture RCA with high affinity is an intriguing alternative, as this creates a surface with autoregulatory activity upon exposure to blood. We therefore screened two variable cysteine-constrained phage-displayed peptide libraries for factor H-binding peptides. We discovered three peptide classes that differed with respect to their main target binding areas. Peptides binding to the broad middle region of factor H (domains 5-18) were of particular interest, as they do not interfere with either regulatory or binding activities. One peptide in this group (5C6) was further characterized and showed high factor H-capturing activity while retaining its functional integrity. Most importantly, when 5C6 was coated to a model polystyrene surface and exposed to human lepirudin-anticoagulated plasma, the bound peptide captured factor H and substantially inhibited complement activation by the alternative pathway. Our study therefore provides a promising and novel approach to produce therapeutic materials with enhanced biocompatibility.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21339361      PMCID: PMC3123137          DOI: 10.4049/jimmunol.1003802

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  60 in total

1.  C3 adsorbed to a polymer surface can form an initiating alternative pathway convertase.

Authors:  Jonas Andersson; Kristina Nilsson Ekdahl; Rolf Larsson; Ulf R Nilsson; Bo Nilsson
Journal:  J Immunol       Date:  2002-06-01       Impact factor: 5.422

2.  Effects of extracorporeal circulation and heparin on the phenotype of platelet surface antigens following heart surgery.

Authors:  A Wahba; G Rothe; H Lodes; S Barlage; G Schmitz; D E Birnbaum
Journal:  Thromb Res       Date:  2000-03-15       Impact factor: 3.944

3.  Plasma protein adsorption pattern on characterized ceramic biomaterials.

Authors:  A Rosengren; E Pavlovic; S Oscarsson; A Krajewski; A Ravaglioli; A Piancastelli
Journal:  Biomaterials       Date:  2002-02       Impact factor: 12.479

4.  Binding of a model regulator of complement activation (RCA) to a biomaterial surface: surface-bound factor H inhibits complement activation.

Authors:  J Andersson; R Larsson; R Richter; K N Ekdahl; B Nilsson
Journal:  Biomaterials       Date:  2001-09       Impact factor: 12.479

5.  Binding kinetics, structure-activity relationship, and biotransformation of the complement inhibitor compstatin.

Authors:  A Sahu; A M Soulika; D Morikis; L Spruce; W T Moore; J D Lambris
Journal:  J Immunol       Date:  2000-09-01       Impact factor: 5.422

6.  Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation.

Authors:  Tom Eirik Mollnes; Ole-Lars Brekke; Michael Fung; Hilde Fure; Dorte Christiansen; Grethe Bergseth; Vibeke Videm; Knut Tore Lappegård; Jörg Köhl; John D Lambris
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

7.  Inhibitor of complement, Compstatin, prevents polymer-mediated Mac-1 up-regulation of human neutrophils independent of biomaterial type tested.

Authors:  S Schmidt; G Haase; E Csomor; R Lütticken; H Peltroche-Llacsahuanga
Journal:  J Biomed Mater Res A       Date:  2003-09-01       Impact factor: 4.396

8.  Optimal heparin surface concentration and antithrombin binding capacity as evaluated with human non-anticoagulated blood in vitro.

Authors:  Jonas Andersson; Javier Sanchez; Kristina Nilsson Ekdahl; Graciela Elgue; Bo Nilsson; Rolf Larsson
Journal:  J Biomed Mater Res A       Date:  2003-11-01       Impact factor: 4.396

9.  Role of membrane cofactor protein (CD46) in regulation of C4b and C3b deposited on cells.

Authors:  Maria L Barilla-LaBarca; M Kathryn Liszewski; John D Lambris; Dennis Hourcade; John P Atkinson
Journal:  J Immunol       Date:  2002-06-15       Impact factor: 5.422

10.  The central portion of factor H (modules 10-15) is compact and contains a structurally deviant CCP module.

Authors:  Christoph Q Schmidt; Andrew P Herbert; Haydyn D T Mertens; Mara Guariento; Dinesh C Soares; Dusan Uhrin; Arthur J Rowe; Dmitri I Svergun; Paul N Barlow
Journal:  J Mol Biol       Date:  2009-10-14       Impact factor: 5.469

View more
  28 in total

Review 1.  From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage.

Authors:  Dimitrios C Mastellos; Edimara S Reis; Despina Yancopoulou; George Hajishengallis; Daniel Ricklin; John D Lambris
Journal:  Immunobiology       Date:  2016-06-16       Impact factor: 3.144

2.  Tailoring biomaterial surface properties to modulate host-implant interactions: implication in cardiovascular and bone therapy.

Authors:  Settimio Pacelli; Vijayan Manoharan; Anna Desalvo; Nikita Lomis; Kartikeya Singh Jodha; Satya Prakash; Arghya Paul
Journal:  J Mater Chem B       Date:  2015-10-16       Impact factor: 6.331

3.  Bypassing adverse injection reactions to nanoparticles through shape modification and attachment to erythrocytes.

Authors:  Peter Popp Wibroe; Aaron C Anselmo; Per H Nilsson; Apoorva Sarode; Vivek Gupta; Rudolf Urbanics; Janos Szebeni; Alan Christy Hunter; Samir Mitragotri; Tom Eirik Mollnes; Seyed Moein Moghimi
Journal:  Nat Nanotechnol       Date:  2017-04-10       Impact factor: 39.213

Review 4.  Complement component C3 - The "Swiss Army Knife" of innate immunity and host defense.

Authors:  Daniel Ricklin; Edimara S Reis; Dimitrios C Mastellos; Piet Gros; John D Lambris
Journal:  Immunol Rev       Date:  2016-11       Impact factor: 12.988

Review 5.  New milestones ahead in complement-targeted therapy.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Semin Immunol       Date:  2016-06-16       Impact factor: 11.130

Review 6.  Therapeutic control of complement activation at the level of the central component C3.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Immunobiology       Date:  2015-06-10       Impact factor: 3.144

7.  Complement activation turnover on surfaces of nanoparticles.

Authors:  S M Moghimi; D Simberg
Journal:  Nano Today       Date:  2017-04-12       Impact factor: 20.722

Review 8.  Manipulating the mediator: modulation of the alternative complement pathway C3 convertase in health, disease and therapy.

Authors:  Daniel Ricklin
Journal:  Immunobiology       Date:  2012-11       Impact factor: 3.144

Review 9.  Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis.

Authors:  Robert A DeAngelis; Edimara S Reis; Daniel Ricklin; John D Lambris
Journal:  Immunobiology       Date:  2012-11       Impact factor: 3.144

Review 10.  Complement therapeutics in inflammatory diseases: promising drug candidates for C3-targeted intervention.

Authors:  D C Mastellos; D Ricklin; E Hajishengallis; G Hajishengallis; J D Lambris
Journal:  Mol Oral Microbiol       Date:  2015-10-07       Impact factor: 3.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.